Phase i study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma

Angevin E.Lopez-Martin J.A.CHIA-CHI LINGschwend J.E.Harzstark A.Castellano D.Soria J.-C.Sen P.Chang J.Shi M.Kay A.Escudier B.2022-09-152022-09-1520131078-0432https://www.scopus.com/inward/record.uri?eid=2-s2.0-84874851836&doi=10.1158%2f1078-0432.CCR-12-2885&partnerID=40&md5=756304ab0c437720d6d41b0e4e16dcbchttps://scholars.lib.ntu.edu.tw/handle/123456789/620322[SDGs]SDG3Phase i study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinomajournal article10.1158/1078-0432.CCR-12-2885233391242-s2.0-84874851836